A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults

A. B M Grudell, Seth Sweetser, Michael Camilleri, Deborah J. Eckert, Maria I Vazquez Roque, Paula J. Carlson, Duane D. Burton, Autumn E. Braddock, Matthew M Clark, Karen M. Graszer, Sarah A. Kalsy, Alan R. Zinsmeister

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background & Aims: Weight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate α2A adrenoreceptor, 5-HT transporter, and GNβ3 genes and weight loss with sibutramine. Methods: We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants. We measured body weight, body mass index, body composition, gastric emptying, and genetic variation (α2A C1291G, 5-HTTLPR, and GNβ3 C825T genotypes). Analysis of covariance was used to assess treatment effects on and associations of the specific markers of candidate genes with weight loss and body composition. Results: Sibutramine, 10 and 15 mg, caused weight loss (P = .009); there was a statistically significant gene by dose interaction for GNβ3 genotype. For each candidate gene, significant treatment effects at 12 weeks were observed (P < .017) for all specific genotype variants (Δ weight loss in the 2 sibutramine doses vs placebo): α2A CC (Δ, ∼5 kg), GNβ3 TC/TT (Δ, ∼6 kg), and 5-HTTLPR LS/SS (Δ, ∼4.5 kg). Gene pairs resulted in significantly greater sibutramine treatment effects on weight (both P < .002): in participants with 5-HTTLPR LS/SS with GNβ3 TC/TT; Δ, ∼6 kg and those with α2A CC with GNβ3 TC/TT; Δ, ∼8 kg; however, effects were not synergistic. Treatment with sibutramine also resulted in significantly greater reduction of body fat for specific α2A CC and GNβ3 TC/TT genotype variants individually (both P < .02). Conclusions: Patient selection based on candidate genes may enhance response to multidimensional sibutramine and behavioral therapy for obesity.

Original languageEnglish (US)
Pages (from-to)1142-1154
Number of pages13
JournalGastroenterology
Volume135
Issue number4
DOIs
StatePublished - Oct 2008

Fingerprint

sibutramine
Pharmacogenetics
Body Composition
Weight Loss
Genotype
Genes
Therapeutics
Placebos
Gastric Emptying
Double-Blind Method

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults. / Grudell, A. B M; Sweetser, Seth; Camilleri, Michael; Eckert, Deborah J.; Vazquez Roque, Maria I; Carlson, Paula J.; Burton, Duane D.; Braddock, Autumn E.; Clark, Matthew M; Graszer, Karen M.; Kalsy, Sarah A.; Zinsmeister, Alan R.

In: Gastroenterology, Vol. 135, No. 4, 10.2008, p. 1142-1154.

Research output: Contribution to journalArticle

Grudell, ABM, Sweetser, S, Camilleri, M, Eckert, DJ, Vazquez Roque, MI, Carlson, PJ, Burton, DD, Braddock, AE, Clark, MM, Graszer, KM, Kalsy, SA & Zinsmeister, AR 2008, 'A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults', Gastroenterology, vol. 135, no. 4, pp. 1142-1154. https://doi.org/10.1053/j.gastro.2008.07.009
Grudell, A. B M ; Sweetser, Seth ; Camilleri, Michael ; Eckert, Deborah J. ; Vazquez Roque, Maria I ; Carlson, Paula J. ; Burton, Duane D. ; Braddock, Autumn E. ; Clark, Matthew M ; Graszer, Karen M. ; Kalsy, Sarah A. ; Zinsmeister, Alan R. / A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults. In: Gastroenterology. 2008 ; Vol. 135, No. 4. pp. 1142-1154.
@article{94baa86b7b8446ccbbf2d2aaa20f7ffa,
title = "A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults",
abstract = "Background & Aims: Weight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate α2A adrenoreceptor, 5-HT transporter, and GNβ3 genes and weight loss with sibutramine. Methods: We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants. We measured body weight, body mass index, body composition, gastric emptying, and genetic variation (α2A C1291G, 5-HTTLPR, and GNβ3 C825T genotypes). Analysis of covariance was used to assess treatment effects on and associations of the specific markers of candidate genes with weight loss and body composition. Results: Sibutramine, 10 and 15 mg, caused weight loss (P = .009); there was a statistically significant gene by dose interaction for GNβ3 genotype. For each candidate gene, significant treatment effects at 12 weeks were observed (P < .017) for all specific genotype variants (Δ weight loss in the 2 sibutramine doses vs placebo): α2A CC (Δ, ∼5 kg), GNβ3 TC/TT (Δ, ∼6 kg), and 5-HTTLPR LS/SS (Δ, ∼4.5 kg). Gene pairs resulted in significantly greater sibutramine treatment effects on weight (both P < .002): in participants with 5-HTTLPR LS/SS with GNβ3 TC/TT; Δ, ∼6 kg and those with α2A CC with GNβ3 TC/TT; Δ, ∼8 kg; however, effects were not synergistic. Treatment with sibutramine also resulted in significantly greater reduction of body fat for specific α2A CC and GNβ3 TC/TT genotype variants individually (both P < .02). Conclusions: Patient selection based on candidate genes may enhance response to multidimensional sibutramine and behavioral therapy for obesity.",
author = "Grudell, {A. B M} and Seth Sweetser and Michael Camilleri and Eckert, {Deborah J.} and {Vazquez Roque}, {Maria I} and Carlson, {Paula J.} and Burton, {Duane D.} and Braddock, {Autumn E.} and Clark, {Matthew M} and Graszer, {Karen M.} and Kalsy, {Sarah A.} and Zinsmeister, {Alan R.}",
year = "2008",
month = "10",
doi = "10.1053/j.gastro.2008.07.009",
language = "English (US)",
volume = "135",
pages = "1142--1154",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults

AU - Grudell, A. B M

AU - Sweetser, Seth

AU - Camilleri, Michael

AU - Eckert, Deborah J.

AU - Vazquez Roque, Maria I

AU - Carlson, Paula J.

AU - Burton, Duane D.

AU - Braddock, Autumn E.

AU - Clark, Matthew M

AU - Graszer, Karen M.

AU - Kalsy, Sarah A.

AU - Zinsmeister, Alan R.

PY - 2008/10

Y1 - 2008/10

N2 - Background & Aims: Weight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate α2A adrenoreceptor, 5-HT transporter, and GNβ3 genes and weight loss with sibutramine. Methods: We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants. We measured body weight, body mass index, body composition, gastric emptying, and genetic variation (α2A C1291G, 5-HTTLPR, and GNβ3 C825T genotypes). Analysis of covariance was used to assess treatment effects on and associations of the specific markers of candidate genes with weight loss and body composition. Results: Sibutramine, 10 and 15 mg, caused weight loss (P = .009); there was a statistically significant gene by dose interaction for GNβ3 genotype. For each candidate gene, significant treatment effects at 12 weeks were observed (P < .017) for all specific genotype variants (Δ weight loss in the 2 sibutramine doses vs placebo): α2A CC (Δ, ∼5 kg), GNβ3 TC/TT (Δ, ∼6 kg), and 5-HTTLPR LS/SS (Δ, ∼4.5 kg). Gene pairs resulted in significantly greater sibutramine treatment effects on weight (both P < .002): in participants with 5-HTTLPR LS/SS with GNβ3 TC/TT; Δ, ∼6 kg and those with α2A CC with GNβ3 TC/TT; Δ, ∼8 kg; however, effects were not synergistic. Treatment with sibutramine also resulted in significantly greater reduction of body fat for specific α2A CC and GNβ3 TC/TT genotype variants individually (both P < .02). Conclusions: Patient selection based on candidate genes may enhance response to multidimensional sibutramine and behavioral therapy for obesity.

AB - Background & Aims: Weight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate α2A adrenoreceptor, 5-HT transporter, and GNβ3 genes and weight loss with sibutramine. Methods: We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants. We measured body weight, body mass index, body composition, gastric emptying, and genetic variation (α2A C1291G, 5-HTTLPR, and GNβ3 C825T genotypes). Analysis of covariance was used to assess treatment effects on and associations of the specific markers of candidate genes with weight loss and body composition. Results: Sibutramine, 10 and 15 mg, caused weight loss (P = .009); there was a statistically significant gene by dose interaction for GNβ3 genotype. For each candidate gene, significant treatment effects at 12 weeks were observed (P < .017) for all specific genotype variants (Δ weight loss in the 2 sibutramine doses vs placebo): α2A CC (Δ, ∼5 kg), GNβ3 TC/TT (Δ, ∼6 kg), and 5-HTTLPR LS/SS (Δ, ∼4.5 kg). Gene pairs resulted in significantly greater sibutramine treatment effects on weight (both P < .002): in participants with 5-HTTLPR LS/SS with GNβ3 TC/TT; Δ, ∼6 kg and those with α2A CC with GNβ3 TC/TT; Δ, ∼8 kg; however, effects were not synergistic. Treatment with sibutramine also resulted in significantly greater reduction of body fat for specific α2A CC and GNβ3 TC/TT genotype variants individually (both P < .02). Conclusions: Patient selection based on candidate genes may enhance response to multidimensional sibutramine and behavioral therapy for obesity.

UR - http://www.scopus.com/inward/record.url?scp=53049092135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53049092135&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2008.07.009

DO - 10.1053/j.gastro.2008.07.009

M3 - Article

C2 - 18725220

AN - SCOPUS:53049092135

VL - 135

SP - 1142

EP - 1154

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -